GlassScriptPhysician profile
Amanda Diane Bratcher
NPI 1023635554
$4,987.50
in general payments reported to CMS, 2019-2025
34 companies · $802 in 2025
The $802 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $744 · 2022: $813 · 2023: $1,188 · 2024: $1,441 · 2025: $802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,388 · Education: $42.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,387.70 |
| Education | $42.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,083.47 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $565.35 | 2021-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $494.16 | 2021-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $310.09 | 2022-2025 | Stelara, Simponi, Simponi Aria |
| Pfizer INC. | $266.96 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $195.27 | 2021-2023 | |
| Gilead Sciences, INC. | $186.31 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $167.91 | 2021-2023 | Dificid |
| Phathom Pharmaceuticals, INC. | $160.57 | 2023-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $157.41 | 2022-2025 | Dupixent |
| Genzyme Corporation | $139.15 | 2023-2025 | |
| Lilly USA, LLC | $133.41 | 2023-2025 | Omvoh |
| Ardelyx, INC. | $114.49 | 2023-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $106.17 | 2024-2025 | Zenpep |
| Qol Medical, LLC | $100.56 | 2021-2025 | Sucraid |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $99.23 | 2021-2024 | Zeposia |
| Organon LLC | $94.87 | 2023-2024 | Hadlima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.40 | 2023-2024 | Cyltezo |
| Celltrion USA INC. | $65.27 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Daiichi Sankyo INC. | $59.73 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $57.22 | 2022 | |
| Intercept Pharmaceuticals, INC. | $48.55 | 2023-2024 | Ocaliva |
| Fresenius Kabi USA, LLC | $43.97 | 2023-2024 | |
| Braintree Laboratories, INC. | $41.51 | 2025 | Suflave |
| Redhill Biopharma INC. | $34.42 | 2021 | |
| Madrigal Pharmaceuticals | $24.23 | 2024 | Resmetirom |
| Sandoz INC. | $23.96 | 2023 | Hyrimoz |
| Alnylam Pharmaceuticals INC. | $22.24 | 2022 | |
| Medtronic, INC. | $21.79 | 2022 | |
| Ethicon US, LLC | $21.71 | 2022 | |
| Mallinckrodt Hospital Products INC. | $19.81 | 2023 | Terlivaz |
| Agios Pharmaceuticals, INC. | $19.57 | 2025 | Pyrukynd |
| Sanofi-Aventis U.S. LLC | $17.94 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.80 | 2024 | Simlandi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Bratcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.